Clinical Pharmacology Research Program
What We Do

The overall goal of the Clinical Pharmacology Research Program, headed by Joan T. Merrill, M.D., is to enhance translational research at OMRF, linking basic research discoveries to clinical trials in patients. The program currently focuses on cardiovascular and immune-modifying therapies.
Recent scientific work has helped to illuminate the specific kinds of blood vessel damage caused by lupus, atherosclerosis, hypertension and diabetes on a molecular level. This has led to new ideas for immune-regulating and blood-vessel-regulating therapies for these diseases. But while there are now several new classes of medicine in the pipeline to treat these life-threatening diseases, we have much to learn about the best dosing and timing to optimize the effectiveness of these new drugs and how to minimize their potential side effects.
Traditionally, gaps have existed between the basic scientific work that gives rise to new medicines and the process by which physicians test these treatments in humans. By connecting basic science investigations directly to clinical trials, we are creating a two-way scientific synergy.
Input from the laboratory will help clinicians better understand how the medicines work and how to use them with optimal safety and effectiveness. Conversely, materials donated by patients in clinical trials may shed important light on the fundamental problems that cause disease in the first place. With the help of applied laboratory science, this information may lead to even better medicines in the future.
Our Scientists
Our Publications

* Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, Merrill JT, McCune WJ, Sawalha AH. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2013. [Abstract] EPub
* Deng Y, Zhao J, Sakurai D, Kaufman KM, Edberg JC, Kimberly RP, Kamen DL, Gilkeson GS, Jacob CO, Scofield RH, Langefeld CD, Kelly JA, Ramsey-Goldman R, Petri MA, Reveille JD, Vila LM, Alarcon GS, Vyse TJ, Pons-Estel BA, gentine Collaborative Group, Freedman BI, Gaffney PM, Sivils KM, James JA, Gregersen PK, Anaya JM, Niewold TB, Merrill JT, Criswell LA, Stevens AM, Boackle SA, Cantor RM, Chen W, Grossman JM, Hahn BH, Harley JB, Alarcon-Riquelme ME, BIOLUPUS and GENLES Networks, Brown EE, Tsao BP. MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus. PLoS Genet 9:e1003336, 2013. [Abstract]
* Kaufman KM, Zhao J, Kelly JA, Hughes T, Adler A, Sanchez E, Ojwang JO, Langefeld CD, Ziegler JT, Williams AH, Comeau ME, Marion MC, Glenn SB, Cantor RM, Grossman JM, Hahn BH, Song YW, Yu CY, James JA, Guthridge JM, Brown EE, Alarcon GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri MA, Reveille JD, Vila LM, Anaya JM, Boackle SA, Stevens AM, Freedman BI, Criswell LA, Pons-Estel BA, on behalf of the Argentine Collaborative Group, Lee JH, Lee JS, Chang DM, Scofield RH, Gilkeson GS, Merrill JT, Niewold TB, Vyse TJ, Bae SC, Alarcon-Riquelme ME, on behalf of the BIOLUPUS network, Jacob CO, Sivils KM, Gaffney PM, Harley JB, Sawalha AH, Tsao BP. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis 72:437-444,2013. [Abstract]
Merrill JT. Co-stimulatory molecules as targets for treatment of lupus. Clin Immunol 2013. [Abstract] EPub
* Molineros JE, Maiti AK, Sun C, Looger LL, Han S, Kim-Howard X, Glenn S, Adler A, Kelly JA, Niewold TB, Gilkeson GS, Brown EE, Alarcon GS, Edberg JC, Petri M, Ramsey-Goldman R, Reveille JD, Vila LM, Freedman BI, Tsao BP, Criswell LA, Jacob CO, Moore JH, Vyse TJ, Langefeld CL, Guthridge JM, Gaffney PM, Moser KL, Scofield RH, Alarcon-Riquelme ME, BIOLUPUS Network, Williams SM, Merrill JT, James JA, Kaufman KM, Kimberly RP, Harley JB, Nath SK. Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production. PLoS Genet 9:e1003222, 2013. [Abstract]
Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcon GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Arranow C, Mackay M, Ramos-Casals M, Van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013. [Abstract] EPub
Peterfy CG, Olech E, Dicarlo JC, Merrill JT, Countryman PJ, Gaylis NB. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther 15:R44, 2013. [Abstract]
* Ramos PS, Oates JC, Kamen DL, Williams AH, Gaffney PM, Kelly JA, Kaufman KM, Kimberly RP, Niewold TB, Jacob CO, Tsao BP, Alarcón GS, Brown EE, Edberg JC, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM, James JA, Guthridge JM, Merrill JT, Boackle SA, Freedman BI, Scofield RH, Stevens AM, Vyse TJ, Criswell LA, Moser KL, Alarcón-Riquelme ME, Langefeld CD, Harley JB, Gilkeson GS. Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry. J Rheumatol 2013. [Abstract] EPub
Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC. Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. J Rheumatol 40:579-589, 2013. [Abstract]
Thanou A, Merrill JT. Top 10 things to know about lupus activity measures. Curr Rheumatol Rep 15:334, 2013. [Abstract]
* Indicates publications by more than one department.
Contact Us

Clinical Pharmacology Research Program
Oklahoma Medical Research Foundation
825 NE 13th Street, MS 22
Oklahoma City, OK 73104
Phone: (405) 271-7805
Fax: (405) 271-8797
Email: clinic@omrf.org


